Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A gene-based immunotherapy called aglatimagene besadenovec (CAN-2409), combined with radiation, significantly reduced prostate cancer recurrence in intermediate-risk patients. Data from the phase 3 PrTK03 trial showed a 41% lower risk of recurrence or cancer-specific death vs. placebo plus radiation. A companion study also confirmed durable immune activation, with expanded cancer-fighting T-cells in the bloodstream.
A gene-based immunotherapy, aglatimagene besadenovec (CAN-2409), is showing meaningful promise in prostate cancer treatment. When combined with external beam radiation therapy (EBRT), it cut the risk of cancer recurrence or prostate cancer–specific death by 41% compared to placebo plus radiation in intermediate-risk localized prostate cancer patients — and the immune benefits appear to last well beyond treatment.
These findings come from the phase 3 PrTK03 trial and the phase 2 PrTK05 study. Beyond survival data, more patients in the CAN-2409 arm had negative biopsies at 22–26 months post-treatment, and immune monitoring revealed a meaningful expansion of cancer-fighting CD8+ T-cells circulating in the blood — a sign the therapy is triggering a systemic immune response, not just a local one.
By the Numbers:
Why it matters: These results strengthen the case for immunotherapy as a viable addition to standard radiation in prostate cancer — and hint at broader potential in metastatic solid tumors where systemic immune control is critical.
